BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Preventing neuronal necroptosis by disrupting the interaction between ASIC1A, an acid-sensing ion channel, RIPK1 and NSF could treat ischemic stroke. During acidosis, the interaction between ASIC1A’s C- and N-termini is...
BC Innovations | Aug 1, 2019
Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Blocking the long non-coding RNA LINC01139 could sensitize checkpoint inhibitor-resistant triple-negative breast cancer (TNBC) to the therapies. High LINC01139 expression levels correlated with low tumor levels of antigen-presenting cells...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Innovations | Jan 16, 2019
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in...
BC Innovations | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

New Therapeutic Targets and Biomarkers: November 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Nov 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest miR-584-5p could help treat medulloblastoma. In patient tissue samples or tumor cells from patient-derived xenograft (PDX) mouse models of medulloblastoma, miR-584-5p levels were lower...
BC Week In Review | Nov 2, 2018
Clinical News

NIH pauses stem cell trial after Brigham calls to retract 'fabricated' foundational research

NIH's National Heart, Lung, and Blood Institute (NHLBI) said Oct. 29 it will pause the Phase II CONCERT-HF trial testing a cardiac stem cell therapy as recent calls for retraction of journal articles in related...
BC Extra | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
BC Innovations | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 84
BioCentury | Feb 25, 2020
Distillery Therapeutics

Inhibiting necroptosis to treat ischemic stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Preventing neuronal necroptosis by disrupting the interaction between ASIC1A, an acid-sensing ion channel, RIPK1 and NSF could treat ischemic stroke. During acidosis, the interaction between ASIC1A’s C- and N-termini is...
BC Innovations | Aug 1, 2019
Distillery Therapeutics

Sensitizing cancer to checkpoint inhibitors by targeting the non-coding RNA LINC01139

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Blocking the long non-coding RNA LINC01139 could sensitize checkpoint inhibitor-resistant triple-negative breast cancer (TNBC) to the therapies. High LINC01139 expression levels correlated with low tumor levels of antigen-presenting cells...
BC Innovations | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BC Extra | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

Sanofi (Euronext:SAN; NASDAQ:SNY) said Ameet Nathwani will become the pharma's first chief digital officer in addition to his current role of EVP, CMO. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said SVP, Business Development and Corporate Strategy Aradhana...
BC Innovations | Jan 16, 2019
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies identified a naphthalenone-based Hsp90 inhibitor that could help treat glioblastoma. Screening of a small molecule library in a HeLa cell-based activity assay, followed by optimization and in...
BC Innovations | Dec 6, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: November 2018

New Therapeutic Targets and Biomarkers: November 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during November. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Nov 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest miR-584-5p could help treat medulloblastoma. In patient tissue samples or tumor cells from patient-derived xenograft (PDX) mouse models of medulloblastoma, miR-584-5p levels were lower...
BC Week In Review | Nov 2, 2018
Clinical News

NIH pauses stem cell trial after Brigham calls to retract 'fabricated' foundational research

NIH's National Heart, Lung, and Blood Institute (NHLBI) said Oct. 29 it will pause the Phase II CONCERT-HF trial testing a cardiac stem cell therapy as recent calls for retraction of journal articles in related...
BC Extra | Oct 17, 2018
Preclinical News

Immune-Onc, University of Texas discover new AML target

A study published Wednesday in Nature revealed a checkpoint inhibitor target for acute myelogenous leukemia, adding a new mechanism of action for an indication that, until recently, has been a new drug wasteland. Immune-Onc Therapeutics...
BC Innovations | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 84